Arcus board member Quigley resigns; Linda Higgins appointed as Gilead designee

Arcus Biosciences, Inc.

Michael Quigley resigned from Arcus board effective upon appointment of Gilead's new designee, following his departure from Gilead.
Linda Higgins, SVP of Research at Gilead, appointed as Class III director; she previously led Biology at Gilead since 2010.
Higgins will not receive compensation for Arcus board service; standard indemnification agreement expected.
Changes effective August 10, 2021, under the Investor Rights Agreement with Gilead dated May 2020.

item 5.02

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

Linda Higgins

Director

RCUS · Arcus Biosciences, Inc.

Effective: 2021-08-10
Filed: August 11, 2021, 7:59 PM ET

On August 10, 2021, the Board appointed Linda Higgins, Senior Vice President of Research, External Innovation at Gilead, as a Class III director to fill the vacancy left by Dr. Quigley’s resignation.

Departed

Michael Quigley

Director

RCUS · Arcus Biosciences, Inc.

Effective: 2021-08-10
Successor: Linda Higgins
Filed: August 11, 2021, 7:59 PM ET

Michael Quigley, Ph.D., resigned as a member of Arcus Biosciences, Inc.’s Board of Directors, effective upon the appointment of Gilead’s new director designee

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Linda Higgins was appointed as Director at Arcus Biosciences, Inc..

Action: appointed
Role: Director

Exact text from the filing

On August 10, 2021, the Board appointed Linda Higgins, Senior Vice President of Research, External Innovation at Gilead, as a Class III director to fill the vacancy left by Dr. Quigley’s resignation.

View on SEC.gov

Executive change SEC 8-K Item 5.02 confidence 0.95

Michael Quigley resigned as Director at Arcus Biosciences, Inc..

Action: resigned
Role: Director

Exact text from the filing

Michael Quigley, Ph.D., resigned as a member of Arcus Biosciences, Inc.’s Board of Directors, effective upon the appointment of Gilead’s new director designee

View on SEC.gov

Arcus Biosciences, Inc. filing history →

Source: SEC EDGAR

accession 0001564590-21-043472

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.